Intergroup collaboration in ovarian cancer: The Gynecologic Cancer Intergroup (GCIG)

International Journal of Gynecological Cancer

Volumn 11, Issue SUPPL. 1, 2001, Pages 73-76

  Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Gynecologic Cancer Intergroup; Intergroup collaboration; Ovarian cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034884712     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2001.11(suppl.1)sup1073.x     Document Type: Conference Paper

References (13)

1. Randomised trials in ovarian cancer: Trial design considerations
2. Intergroup collaboration in ovarian cancer: A giant step forward
3. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
4. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses from 37 individual trials
5. ICON2: Randomised trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
6. Randomized trial of paclitaxel (PTX) and carboplatin (CBDCA) vs a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin): The third International Collaborative Ovarian Neoplasm study (ICON-3)
7. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
8. Advanced epithelial ovarian cancer: 1998 Consensus statements
9. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
10. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC)
11. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
12. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
13. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)